Clinical Trial Update: A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 trial describing safety and immunogenicity of a Pfizer RSV vaccine in healthy adults has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Tract Infections

Drugs mentioned

• RSV vaccine (respiratory syncytial virus vaccine)

Snippet

Sponsor: Pfizer | Conditions: Respiratory Tract Infections | Phase 2 | Status: COMPLETED | Results posted: 2021-03-04